Dabrafenib

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.

May is Brain Cancer Awareness Month.

The FDA approved dabrafenib with trametinib for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy.

In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

The FDA granted accelerated approval to dabrafenib plus trametinib for treatment of certain patients with unresectable or metastatic solid tumors that harbor BRAF V600E mutations.

CHICAGO — A combination of two targeted therapies significantly improved outcomes compared with standard care for children with BRAF V600 mutation-positive low-grade glioma, according to study results presented at ASCO Annual Meeting.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

Dabrafenib plus trametinib exhibited encouraging activity among patients with recurrent or refractory BRAF V600E mutation-positive glioma, according to study results.

Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.